ESTRO 2024 - Abstract Book

S1428

Clinical - Head & neck

ESTRO 2024

swallowing (62%), and xerostomia (64%). Seven (50%) reported that their swallowing ability both limited their day-to day activities and made them embarrassed by their eating habits. Seven (54%) reported that swallowing took great effort. Five (36%) stated they had low self-esteem secondary to their swallowing issues. Six patients (42%) described anxiety secondary to their cancer with mild pain an issue for 5 patients (42%). Compared to the month prior to treatment, 5 (36%) reported their current health related QOL as better, 5 (35%) the same and 4 (28%) as worse. Eleven (73%) reported their health related QOL as good (or better) in the previous 7 days.

Conclusion:

Table 1. Patient Characteristics

Overall (N=57)

Age

Median (Min, Max)

64 (45, 86)

Outcomes stage hypopharyngeal cancer treated with IMRT are reasonable with disease control rates of 63.2%. Encouragingly two thirds of patients describe equivalent or better health than prior to treatment at last follow up. Late patient reported swallowing toxicity is however significant with over half of patients complaining of being limited in daily activity due to problems with swallowing. Meticulous planning of radiotherapy to minimise dose to swallowing structures and appropriate multi for early

Gender

Male

38 19 41

Female

Disease Subsite

Pyriform Fossa

Posterior Cricoid 9 Posterior Pharyngeal Wall 7

AJCC Staging

I

4

II

35 18 37 20 48

III

Radiotherapy Fractionation 66Gy/30Fr

55Gy/20Fr

Treatment

RT Alone

((CT)RT)

9

disciplinary team (MDT) support to optimise swallow outcomes is indicated.

Keywords: hypopharynx, PROM's, Head and neck

2768

Poster Discussion

Patterns of failure: Recurrence location for head-and-neck cancer patients after radiotherapy

Cornelis P.J. Raaijmakers 1 , Barbara Paic 1 , Alexis N.T.J. Kotte 1 , Patricia A.H. Doornaert 1 , Chris H.J. Terhaard 1 , Johannes A Rijken 2 , Remco de Bree 2 , Mischa de Ridder 1 1 UMC Utrecht, Radiation Oncology, Utrecht, Netherlands. 2 UMC Utrecht, Head and Neck Surgical Oncology, Utrecht, Netherlands

Purpose/Objective:

About 20% of all treated patients with Head and neck squamous cell carcinoma (HNSCC) cancer have recurrent disease. For patients treated with radiotherapy it is essential to know the exact location of the recurrence to check the quality of the treatment, but also to help understand the biology of the cancer. Key point that is lacking in current knowledge of recurrences is the exact recurrence location The aim of this research was to determine the